TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05617885
Drug: GNRH-A Leuprolide Acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered via intramuscular injection, per standard of care. GnRH agonist is a hormonal therapy drug.
Study: NCT05617885
Drug: GNRH-A Goserelin
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered via subcutaneous injection, per standard of care. GnRH agonist is a hormonal therapy drug.
Study: NCT05617885
Drug: Degarelix
Normalized name: Degarelix
DrugBank: Degarelix (DB06699)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered via subcutaneous injection, per standard of care. GnRH antagonist is a hormonal therapy drug.
Study: NCT05183984
Drug: Bevacizumab-Awwb
Normalized name: bevacizumab-awwb
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: MVASI (bevacizumab biosimilar) will be administrated by intravenous infusion at the second chemotherapy cycle for 5 cycles.~the administration will continue during maintenance phase. Total bevacizumab duration therapy is 15 months.
Study: NCT05183984
Drug: Niraparib
Normalized name: Niraparib
DrugBank: Niraparib (DB11793)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: niraparib will be administered orally once daily continuously after chemotherapy (+/- bevacizumab) cycles (maintenance treatment period). Total niraparib duration mainance treatment period is 2 years.
Study: NCT05205837
Drug: Letrozole 2.5mg, hCG
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug -Treatment Intramuscular injektion - Treatment
Study: NCT05594914
Drug: AK104
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: AK104 plus TC regimen(paclitaxel liposome , carboplatin), once every 3 weeks (Q3W), induction treatment for 2 cycles; Subsequently, AK104 plus TC regimen is combined with radiotherapy for 2 cycles.
Study: NCT05462496
Drug: Ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin and metronidazole will be initiated 7 days following 5th dose of FOLFIRINOX. Subjects will self-administer ciprofloxacin 500mg PO BID on days 1-21. Participants will be instructed to take the antibiotics with food to minimize stomach upset and to administer at the same time each day. Treatment with antibiotics will continue for 21 days unless there is unacceptable toxicity or disease progression. Subjects will record date, time and number of tablets they take on provided drug diaries.
Study: NCT05462496
Drug: Metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin and metronidazole will be initiated 7 days following 5th dose of FOLFIRINOX. Subjects will self-administer metronidazole 500mg PO every 8 hours on days 1-21. Participants will be instructed to take the antibiotics with food to minimize stomach upset and to administer at the same time each day. Treatment with antibiotics will continue for 21 days unless there is unacceptable toxicity or disease progression. Subjects will record date, time and number of tablets they take on provided drug diaries.
Study: NCT05462496
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab will be initiated 7 days post initiation of antibiotics. Subjects will receive a flat dose of pembrolizumab 200mg IV over 30 minutes.
Study: NCT05737680
Drug: Hydroxychloroquine
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine 400mg daily
Study: NCT04571580
Drug: Reteplase Injection 9mg
Normalized name: reteplase Injection
DrugBank: Reteplase (DB00015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: low-dose intracoronary fibrinolytic therapy with reteplase 9mg
Study: NCT04571580
Drug: Reteplase Injection 18mg
Normalized name: reteplase Injection
DrugBank: Reteplase (DB00015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: low-dose intracoronary fibrinolytic therapy with reteplase 18mg
Study: NCT06226363
Drug: LNF1901 Monoclonal Antibody Injection
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: LNF1901，7 dose groups:0.003mg/kg、0.03mg/kg、0.1mg/kg、0.3mg/kg、1mg/kg、2mg/kg、3mg/kg，IV, infusion time 60min±10min, Q3W, until disease progression or other reasons to stop treatment, the longest administration to 2 years, whichever occurs first.
Study: NCT05737680
Drug: Colchicine
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colchicine continued
Study: NCT06230146
Drug: Insulin group
Normalized name: INSULIN
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fractional ablative laser followed by Intralesional insulin injection (Human actrapid insulin 100 IU\\ml solution).~Dose: injection of 0.1 ml\\cm3 of the lesion avoiding subcutaneous injection as much as possible especially in fatty areas.
Study: NCT06230146
Drug: Botulinum toxin group
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Fractional ablative laser followed by intralesional Botox-A (100 U vacuum-dried powder in a single-use vial for reconstitution diluted in 2 mL of sterile, preservative-free 0.9% saline to constitute a solution at a concentration of 5 U/0.1 mL),It will be injected into the body of the keloid with the help of a 24gauge needle at a distance of 1 cm apart until slight blanching is visible. The dose will be adjusted to 2.5 U/cm3 of the lesion, not exceeding 100 units per session.
Study: NCT06230146
Drug: Triamcinolone acetonide group
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fractional ablative laser followed by Triamcinolone acetonide injection. TAC 40 mg/ml will be diluted with normal saline solution 0.9% to the concentration of 20 mg/ml .Maximum drug injected during each session will be 40 mg triamcinolone.
Study: NCT05255666
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 400 mg intravenously
Study: NCT05255666
Drug: Liposomal Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Starting at 50 mg/m\^2. The dose may be increased to 70 mg/m\^2 if tolerated or dose reduced to 35 mg/m\^ if treatment-emergent severe adverse event (TESAE) occurs.
Study: NCT06641674
Drug: 18F-LF13
Normalized name: (18F)-Fluoride
DrugBank: Fluoride ion F-18 (DB09398)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18F-LF13 PET/CT: after intravenous injection of 1.85 - 3.7 MBq/kg body weight of quality-controlled 18F-LF13, a Siemens Biograph PET/CT scan will be applied within 0.5 h, and the scan range will be from the top of the head to 1/3 of the upper thigh, 2 h to 4 h delayed scanning can be added if necessary.
Study: NCT06640296
Drug: Liposomal Amphotericin B (LAmB)
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: collect data on tolerability and effectiveness of liposomal amphotericin B prophylaxis
Study: NCT06015516
Drug: Minoxidil Tablets
Normalized name: Minoxidil Tablets
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Since oral minoxidil is a new formulation and, according to the recommendations of the Regulatory Authorities, it is considered appropriate to carry out a multiple dose study to evaluate and to compare the bioavailability between both formulations (oral versus topical solution), measuring the plasma concentrations of minoxidil.~Achievement of steady-state is assessed by comparing at least three pre-dose concentrations for each formulation, as half-life of minoxidil is around 4 hours, we will administered 5 doses in each period.
Study: NCT06015516
Drug: Minoxidil topical solution 20 mg/ml
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Since oral minoxidil is a new formulation and, according to the recommendations of the Regulatory Authorities, it is considered appropriate to carry out a multiple dose study to evaluate and to compare the bioavailability between both formulations (oral versus topical solution), measuring the plasma concentrations of minoxidil.~Achievement of steady-state is assessed by comparing at least three pre-dose concentrations for each formulation, as half-life of minoxidil is around 4 hours, we will administered 5 doses in each period.
Study: NCT06563934
Drug: Lenvatinib + PD-1 monoclonal antibody
Normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenvatinib 8mg (≤60 kg body weight) or 12 mg (\> 60 kg body weight) orally once a day.~PD-1 monoclonal antibody 200mg i.v. once every 3 weeks.
Study: NCT06490263
Drug: Mulberry Twig Alkaloids Tablets with multiple dose in overweight or obese subjects
Normalized name: MULBERRY
DrugBank: Broussonetia papyrifera pollen (DB10736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part Three: Administered by swallowing after meals with two distinct dosage groups, taken three times daily.
Study: NCT06434493
Drug: Cisplatin & Gemcitabine intravenous chemotherapy
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Following chemoradiotherapy (PBT + capecitabine), and whilst on the liver transplant waiting list, patients will be offered up to 6 cycles of standard chemotherapy with cisplatin and gemcitabine.
Study: NCT05498870
Drug: Adductor Canal Block (ACB) Only
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive an ACB with lidocaine skin wheal
Study: NCT05498870
Drug: Adductor Canal Block (ACB) + iPACK Block
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive an ACB with iPACK block
Study: NCT06076213
Drug: Artesunate-amodiaquine
Normalized name: Amodiaquine
DrugBank: Amodiaquine (DB00613)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets
Study: NCT05158699
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone topical eye drops
Study: NCT05158699
Drug: Triamcinolone Acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25ml of 40mg/ml (10mg) triamcinolone acetonide (Triesence/Vistrec) will be injected subconjunctivally
Study: NCT04946370
Drug: 225Ac-J591
Normalized name: 225Ac-HuM195
DrugBank: Lintuzumab satetraxetan AC-225 (DB15053)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-emitter Actinium-225 conjugated to the anti-PSMA antibody J591.
Study: NCT04946370
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab will be administered intravenously, 400mg every 6 weeks. Patients may receive maximum 18 cycles of therapy, approximately 2 years.
Study: NCT04624399
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients receive 2 x 3-weekly cycles of Atezolizumab (one infusion on the first day of each cycle) prior to cystectomy surgery.
Study: NCT06554639
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered at a dose of 2.5 mg or 5 mg dependent on HRT dosing regimen via oral tablets.
Study: NCT06554639
Drug: Fludrocortisone acetate
Normalized name: Fludrocortisone Acetate
DrugBank: Fludrocortisone (DB00687)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered at a dose of 0.05 mg per HRT dosing regimen via oral tablets.
Study: NCT06554639
Drug: Diltiazem hydrocholoride
Normalized name: Diltiazem Hydrochloride
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered at a dose of 240 mg per dosing regimen via oral capsule (extended-release).
Study: NCT06641544
Drug: Inetetamab
Normalized name: Inetetamab
DrugBank: Inetetamab (DB17457)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A received Inetetamab+Pertuzumab+TPC, while Group B received Inetetamab+Pyrotinib+TPC.
Study: NCT05155085
Drug: AK002
Normalized name: MONOCLONAL ANTIBODY AK002
DrugBank: Lirentelimab (DB16728)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1(IgG1)monoclonal antibody directed against Siglec-8
Study: NCT06640283
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive the institution's standard treatment during Phase I. If ctDNA remains positive between 8 and 12 weeks after the standard treatment, the participant will be invited to proceed to Phase II, which will consist of intravenous immunotherapy for up to 12 months, or until disease progression or unacceptable toxicity occurs. Continuous monitoring with ctDNA testing will be performed during Phase II.
Study: NCT06637761
Drug: WMTA
Normalized name: Warfarin Sodium
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: White Mineral trioxide aggregates
Study: NCT06640777
Drug: LEAF-4L6715
Normalized name: Belladonna Leaf
DrugBank: Belladonna (DB13913)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEAF-4L6715: Administration at a dose of 200mg , for up to 10 days every 12 hours for the first 2 days, followed by once-a-day dosing for the next 8 days (days 3 through 10).
Study: NCT06639295
Drug: 611
Normalized name: T611
DrugBank: T611 (DB06391)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 611 subcutaneous (SC) injection.
Study: NCT06639282
Drug: Siponimod
Normalized name: SIPONIMOD
DrugBank: Siponimod (DB12371)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Siponimod (formerly known as BAF312 and completed trial NCT #01665144) has been FDA approved since 2019 (IND #076122) for the treatment of multiple sclerosis. Siponimod is an immunomodulator that prevents the egression of T lymphocytes from peripheral lymphoid organs.
Study: NCT06640309
Drug: conventional synthetic antirheumatic drugs
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: methotrexate- leflunomide- sulfasalazine- hydroxychloroquine
Study: NCT06643442
Drug: Empagliflozin Tablets
Normalized name: Empagliflozin Tablets
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Empagliflozin 10mg p.o. once daily (commercially available tablet)
Study: NCT06644105
Drug: cefditoren pivoxil tablets
DrugBank: Cefditoren (DB01066)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: took cefditoren pivoxil tablets 200mg after
Study: NCT06644313
Drug: Vebreltinib
Normalized name: Vebreltinib
DrugBank: Vebreltinib (DB16823)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant treatment stage: Vebreltinib 200mg, bid, po, 2-4 months in total; Surgical treatment stage: CR + PR patients and SD + PD patients who could still undergo surgery will receive radical surgery; Adjuvant treatment stage: CR, PR and SD patients who have been treated surgically: Vebreltinib 200mg, bid, po, up to 2 years/until the disease progressed. PD patients: transferred into medical oncology or/and radiation oncology and receive comprehensive therapy.
Study: NCT06643819
Drug: sacubitril/valsatran(dose maintenance)
DrugBank: Sacubitril (DB09292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: During the 4 weeks of Placebo Run-in Period(Single blind), all participants are treated 1 placebo of CKD-202A(Sacubitril∙Valsartan) 100mg and 1 placebo of D763(Valsartan 80 mg) each, total of 2 oral doses once a day.~After Placebo Run-in Period, During the 4 weeks out of 10 weeks of Treatment Period(Double blind), All TEST1 pariticipants are treated 1 CKD-202A (Sacubitril∙Valsartan) 100 mg and 1 placebo of D763(Valsartan 80 mg) each, total of 2 oral doses once a day.~After 4 weeks of Treatment Period, During the 6 weeks out of 10 weeks of Treatment Period(Double blind), All TEST1 pariticipants are treateed 1 CKD-202A (Sacubitril∙Valsartan) 100 mg, 1 placebo of CKD-202A(Sacubitril∙Valsartan) 200mg, 1 placebo of D764(Valsartan 160 mg) each, and a total of 3 oral doses once a day.
Study: NCT06643819
Drug: sacubitril/valsartan(dose increasing)
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: During the 4 weeks of Placebo Run-in Period(Single blind), all participants are treated 1 placebo of CKD-202A(Sacubitril∙Valsartan) 100mg and 1 placebo of D763(Valsartan 80 mg) each, total of 2 oral doses once a day.~After Placebo Run-in Period, During the 4 weeks out of 10 weeks of Treatment Period(Double blind), All TEST2 pariticipants are treated 1 CKD-202A (Sacubitril∙Valsartan) 100 mg and 1 placebo of D763(Valsartan 80 mg) each, total of 2 oral doses once a day.~After 4 weeks of Treatment Period, During the 6 weeks out of 10 weeks of Treatment Period(Double blind), All TEST1 pariticipants are treateed 1 placebo of CKD-202A (Sacubitril∙Valsartan) 100 mg, 1 CKD-202A(Sacubitril∙Valsartan) 200mg, 1 placebo of D764(Valsartan 160 mg) each, and a total of 3 oral doses once a day.
Study: NCT06643819
Drug: Valsartan
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: During the 4 weeks of Placebo Run-in Period(Single blind), all participants are treated 1 placebo of CKD-202A(Sacubitril∙Valsartan) 100mg and 1 placebo of D763(Valsartan 80 mg) each, total of 2 oral doses once a day. After Placebo Run-in Period, During the 4 weeks out of 10 weeks of Treatment Period(Double blind), All TEST2 pariticipants are treated 1 placebo of CKD-202A (Sacubitril∙Valsartan) 100 mg and 1 D763(Valsartan 80 mg) each, total of 2 oral doses once a day. After 4 weeks of Treatment Period, During the 6 weeks out of 10 weeks of Treatment Period(Double blind), All TEST1 pariticipants are treateed 1 placebo of CKD-202A (Sacubitril∙Valsartan) 100 mg, 1 placebo of CKD-202A(Sacubitril∙Valsartan) 200mg, 1 D764(Valsartan 160 mg) each, and a total of 3 oral doses once a day.
Study: NCT06643585
Drug: Trastuzumab-Deruxtecan
Normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab-Deruxtecan (i.v. 5,4 mg/kg, q3w) + endocrine therapy (if hormonal-receptor-positive) for 16 cycles or until relapse, if earlier
Study: NCT04821310
Drug: Full dose Pantoprazole plus matching placebo
DrugBank: Pantoprazole (DB00213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Full healing dose of pantoprazole plus matching placebo
Study: NCT04821310
Drug: Half Dose Pantoprazole plus matching placebo
DrugBank: Pantoprazole (DB00213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Half healing dose of pantoprazole plus matching placebo
Study: NCT05837897
Drug: Vedolizumab IV
Normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Vedolizumab IV infusion
Study: NCT00002236
Drug: Indinavir sulfate
Normalized name: Indinavir Sulfate
DrugBank: Indinavir (DB00224)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002236
Drug: Delavirdine mesylate
Normalized name: Delavirdine Mesylate
DrugBank: Delavirdine (DB00705)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002236
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06277284
Drug: MG-K10 humanized monoclonal antibody injection (prefilled syringe)
Normalized name: Anti-VEGF Humanized Monoclonal Antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: MG-K10 Humanized Monoclonal Antibody Injection
Study: NCT05258292
Drug: Insulin
Normalized name: Insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin doses will be retrieved from insulin pump reports (for insulin pump users) or journals for (for multiple daily injections users)
Study: NCT06468826
Drug: Avacopan
Normalized name: Avacopan
DrugBank: Avacopan (DB15011)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral capsules
Study: NCT05226338
Drug: D-0502
Normalized name: D
DrugBank: Rosomidnar (DB17154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation 1 Formulation 2 Formulation 3
Study: NCT05254418
Drug: dulaglutide injection
Normalized name: Dulaglutide Injection
DrugBank: Dulaglutide (DB09045)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: All participants will undergo a 4-week run-in phase followed by 12 weeks of treatment (dulaglutide 1.5 mg/wk), followed by 4 weeks of follow up after discontinuing the study medication
Study: NCT04139304
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04139304
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT04139304
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT04139304
Drug: Vincristine Sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT04827030
Drug: Ropivacaïne Hydrochloride by Erector Spinae block
Normalized name: Ropivacaine Hydrochloride
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ropivacaïne Hydrochloride Erector Spinae puncture will be performed with ultrasound guidance. Then 0.50% Ropivacaine hydrochloride will be injected at a dose of 0.6 ml/kg of actual weight, without exceeding 30 ml.
Study: NCT04827030
Drug: Ropivacaïne Hydrochloride by Paravertebral block
Normalized name: Ropivacaine Hydrochloride
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paravertebral puncture will be performed with ultrasound guidance. Then 0.50% Ropivacaine hydrochloride will be injected at a dose of 0.6 ml/kg of actual weight, without exceeding 30 ml.
Study: NCT05941585
Drug: Mitoxantrone hydrochloride liposome injection30mg/m2
DrugBank: Mitoxantrone (DB01204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitoxantrone hydrochloride liposome intravenous infusion on day 1 (30mg/m2)
Study: NCT05941585
Drug: Venetoclax (d4 100mg/day, d5200mg/day ,d6-d12 400mg/day)
Normalized name: venetoclax 100 MG
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Venetoclax d4-d12 (d4 100mg/day, d5200mg/day ,d6-d12 400mg/day)in a 4-week treatment cycle.
Study: NCT05941585
Drug: Cytarabine(standard-dose:d1-d7100mg/m2/day)
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cytarabine intravenous infusion on d1-d7 ,100mg/m2/day
Study: NCT05941585
Drug: Cytarabine(intermediate-dose:d1-d4100mg/m2/day, d5-d7 1g/m2)
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: d1-d4100mg/m2/day, d5-d7 1g/m2
Study: NCT05941585
Drug: Mitoxantrone hydrochloride liposome injection24mg/m2
DrugBank: Mitoxantrone (DB01204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitoxantrone hydrochloride liposome intravenous infusion on day 1 (24mg/m2)